Is adjuvant chemotherapy following retroperitoneal lymph node dissection for nonseminomatous testis cancer necessary?

J. P. Donohue, L. H. Einhorn, S. D. Williams

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The criteria for successful application of adjuvant chemotherapy are: a poor prognosis for cure with primary surgical therapy alone, and evidence that the proposed adjuvant therapy is more effective when used than when withheld. In nonseminomatous testicular tumors, both of these points are at least open to question. Our data suggest that adjuvant chemotherapy is not necessary at all in patients with stage I disease and that it confers no survival advantage for patients with stage II disease. In fact, those patients with stage II disease who receive single drug (actinomycin D) adjuvant therapy appear to fare less well than those who are treated expectantly following node dissection, and who are subsequently treated with combination chemotherapy only at the time of clinical relapse.

Original languageEnglish (US)
Pages (from-to)747-756
Number of pages10
JournalUrologic Clinics of North America
Volume7
Issue number3
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Is adjuvant chemotherapy following retroperitoneal lymph node dissection for nonseminomatous testis cancer necessary?'. Together they form a unique fingerprint.

  • Cite this